Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

被引：19

作者：

Chiappella, Annalisa ^{[1
]}

Dodero, Anna ^{[1
]}

Evangelista, Andrea ^{[2
]}

Re, Alessandro ^{[3
]}

Orsucci, Lorella ^{[4
]}

Usai, Sara Veronica ^{[5
]}

Castellino, Claudia ^{[6
]}

Stefoni, Vittorio ^{[7
]}

Pinto, Antonio ^{[8
]}

Zanni, Manuela ^{[9
]}

Ciancia, Rosanna ^{[10
]}

Ghiggi, Chiara ^{[11
]}

Rossi, Francesca Gaia ^{[12
]}

Arcari, Annalisa ^{[13
]}

Ilariucci, Fiorella ^{[14
]}

Zilioli, Vittorio Ruggero ^{[15
]}

Flenghi, Leonardo ^{[16
]}

Celli, Melania ^{[17
]}

Volpetti, Stefano ^{[18
]}

Benedetti, Fabio ^{[19
]}

Ballerini, Filippo ^{[20
]}

Musuraca, Gerardo ^{[21
]}

Bruna, Riccardo ^{[22
]}

Patti, Caterina ^{[23
]}

Leonardi, Francesco ^{[24
]}

Arcaini, Luca ^{[25
,26
]}

Magagnoli, Massimo ^{[27
]}

Cavallo, Federica ^{[28
]}

Bermema, Anisa ^{[1
]}

Tucci, Alessandra ^{[3
]}

Boccomini, Carola ^{[4
]}

Ciccone, Giovannino ^{[2
]}

Carniti, Cristiana ^{[29
]}

Pileri, Stefano Aldo ^{[30
]}

Corradini, Paolo ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy

[2] Azienda Osped & Univ Citta Salute & Sci & CPO Pie, Unit Clin Epidemiol, Turin, Italy

[3] ASST Spedali Civili Brescia, Hematol Div, Brescia, Italy

[4] Azienda Osped & Univ Citta Salute & Sci, Div Hematol, Turin, Italy

[5] Osped Oncol Armando Businco, Hematol Unit, Cagliari, Italy

[6] Azienda Osped S Croce & Carle, Div Hematol, Cuneo, Italy

[7] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[8] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Hematol Oncol & Stem Cell Transplantat Unit, Naples, Italy

[9] Azienda Osped Santi Antonio & Biagio & Cesare Arr, Div Hematol, Alessandria, Italy

[10] Ctr Riferimento Oncol Aviano CRO IRCCS, Hematol, Aviano, Italy

[11] IRCCS Osped Policlin San Martino, Unit Hematol & Cellular therapies, Genoa, Italy

[12] Fdn IRCCS Ca Granda, Div Hematol, OM Policlin, Milan, Italy

[13] Osped Guglielmo Saliceto, Hematol Unit, Piacenza, Italy

[14] IRCCS Reggio Emilia, Hematol, Azienda USL, Reggio Emilia, Italy

[15] ASST Grande Osped Metropolitano Niguarda, Div Hematol, Milan, Italy

[16] Azienda Osped Perugia, Hematol, Perugia, Italy

[17] Osped Infermi, Hematol, Rimini, Italy

[18] ASUFC, Presidio Osped Univ Santa Maria della Misericordi, Clin Hematol, Udine, Italy

[19] Azienda Osped Univ Verona, Hematol & Stem Cell Transplantat, Verona, Italy

[20] IRCCS Osped Policlin San Martino, Hematol, Genoa, Italy

[21] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Hematol unit, Meldola, Italy

[22] Osped Maggiore La Carita, Div Hematol, Novara, Italy

[23] Azienda Villa Sofia Cervello, Div Onco Hematol, Palermo, Italy

[24] Azienda Osped Univ Parma, Hematol & CTMO, Parma, Italy

[25] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Mol Med, Pavia, Italy

[26] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy

[27] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Dept Oncol & Hematol, Rozzano, Italy

[28] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Div Hematol, Azienda Osped & Univ Citta Salute & Sci, Turin, Italy

[29] Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Lab Hematol, Milan, Italy

[30] European Inst Oncol IRCCS, Div Haematopathol, Milan, Italy

来源：

LEUKEMIA | 2023年 / 37卷 / 02期

关键词：

LONG-TERM REMISSIONS; ALLOGENEIC TRANSPLANTATION; IMPACT;

D O I：

10.1038/s41375-022-01780-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; in first line, Romidepsin was added with CHOP. We designed a study combining romidepsin and CHOEP as induction before HDT + auto-SCT in untreated PTCLs (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18-65 years. A phase Ib/II trial was conducted to define the maximum tolerated dose (MTD) of Ro-CHOEP, and to assess efficacy and safety of 6 Ro-CHOEP as induction before HDT. The study hypothesis was to achieve a 18-month PFS of 70%. Twenty-one patients were enrolled into phase Ib; 7 dose-limiting toxicities were observed, that led to define the MTD at 14 mg/ms. Eighty-six patients were included in the phase II. At a median follow-up of 28 months, the 18-month PFS was 46.2% (95%CI:35.0-56.7), and the 18-month overall survival was 73.1% (95%CI:61.6-81.7). The overall response after induction was 71%, with 62% CRs. No unexpected toxicities were reported. The primary endpoint was not met; therefore, the enrollment was stopped at a planned interim analysis. The addition of romidepsin to CHOEP did not improve the PFS of untreated PTCL patients.

引用

页码：433 / 440

页数：8

共 50 条

[21] High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma:: the GEL-TAMO experience
Rodríguez, J
Caballero, MD
Gutiérrez, A
Marín, J
Lahuerta, JJ
Sureda, A
Carreras, E
León, A
Arranz, R
de Sevilla, AF
Zuazu, J
García-Laraña, J
Rifon, J
Varela, R
Gandarillas, M
SanMiguel, J
Conde, E
ANNALS OF ONCOLOGY, 2003, 14 (12) : 1768 - 1775
[22] A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study
Dupuis, Jehan
Casasnovas, Rene-Olivier
Ghesquieres, Herve
Morschhauser, Franck
Tilly, Herve
Thieblemont, Catherine
Ribrag, Vincent
Coiffier, Bertrand
BLOOD, 2012, 120 (21)
[23] High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Primary CNS Lymphoma: Updated Results from a Pilot and Phase II Study.
Illerhaus, Gerald
Mueller, Fabian
Feuerhake, Friedrich
Finke, Juergen
BLOOD, 2008, 112 (11) : 1229 - 1229
[24] The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives
Yared, Jean
Kimball, Amy
CANCER TREATMENT REVIEWS, 2013, 39 (01) : 51 - 59
[25] Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation
C. Kahl
M. Leithäuser
D. Wolff
B. Steiner
G. Hartung
J. Casper
M. Freund
Annals of Hematology, 2002, 81 : 646 - 650
[26] Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation
Kahl, C
Leithäuser, M
Wolff, D
Steiner, B
Hartung, G
Casper, J
Freund, M
ANNALS OF HEMATOLOGY, 2002, 81 (11) : 646 - 650
[27] Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).
Piekarz, Richard
Wright, John
Frye, Robin
Allen, Steven L.
Joske, David
Kirschbaum, Mark
Lewis, Ian D.
Prince, Miles
Smith, Sonali
Jaffe, Elaine S.
Bates, Susan
BLOOD, 2009, 114 (22) : 661 - 662
[28] High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival
Min Kyoung Kim
Shin Kim
Sung Sook Lee
Sun Jin Sym
Dae Ho Lee
Seongsoo Jang
Chan Jeong Park
Hyun Sook Chi
Jooryung Huh
Cheolwon Suh
Annals of Hematology, 2007, 86 : 435 - 442
[29] The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-Cell lymphoma (PTCL).
Nademanee, Auaypom P.
Zain, Jasmine M.
Palmer, Joycelynne
Tsai, Nicole
Kogut, Neil Martin
Krishnan, Arnrita
Popplewell, Leslie
Rodriguez, Roberto
Smith, Eileen Patricia
Forman, Stephen J.
BLOOD, 2006, 108 (11) : 871A - 871A
[30] High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival
Kim, Min Kyoung
Kim, Shin
Lee, Sung Sook
Sym, Sun Jin
Lee, Dae Ho
Jang, Seongsoo
Park, Chan Jeong
Chi, Hyun Sook
Huh, Jooryung
Suh, Cheolwon
ANNALS OF HEMATOLOGY, 2007, 86 (06) : 435 - 442

← 1 2 3 4 5 →